Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (14570)	12/8/2004 4:05:11 PM
From: scaram(o)uche	Respond to of 52153

We have great parties. There's this storied story..... American Association of Immunologists sorta has it's own house band. I can think of more than one autobiography/memoirs that would sell. :-)

To: Biomaven who wrote (14570)	12/8/2004 10:26:37 PM
From: scaram(o)uche	Respond to of 52153

but, you don't want to try this one on for light reading..... Immunogenetics. 1983;18(5):541-5. Monoclonal antibodies reactive with H-2 determinants. Harmon RC, Stein N, Frelinger JA. It's written in a a language that few practice. It was fun.... while others were focused on a given antibody to a given protein, there were a few classical serologists who were focused on generating multiple antibodies to disctinct regions (epitopes) of a given molecule. George Snell stuff, if anyone has ever read about him. I entered as we were were transitioning to an understanding of cellular responses to self and foreign MHC determinants..... the fundamental pivot point for immune responses. My first postdoctoral fellowship was from Cancer Research Inc., New York. CRI fellowships carried no maximum stipend, and were thus tough to get. Sort of like a Damon Runyon-plus. I believe that there were seven funded, the year I got one. The fellow could ask for whatever stipend the lab director thought was reasonable. Damn Director thought that it would be unfair if I got more than the NIH fellows with whom I'd be working. Grumble, piss, moan. Throw in a massive dollar plummet (location, Max Planck, Tuebingen), and I was starving on THE best fellowship known to Earth. Second postdoc was a Neurology (guffaw!) fellow at USC School of Medicine, courtesy NIH. That's where I did the work described in the citation. Among many other projects, we were collaborating with Lee Hood's lab to be first to a biggie..... the demonstration that the product of a transfected MHC gene could determine MHC-restricted cytotoxicity against a virus. We were also kicking out anti-MHC MAbs like crazy, and I got to bridge some of the world of classical MHC serology (a labyrinth that sucks you in and spits you out an immunologist, whether you're going to like it or not) with MAbs. So, while most authors at the time were describing one MAb and what it did for a couple of years, that paper describes about 35 that react with five molecules of the H-2p haplotype. And then I was done with them. But the language of classical MHC serologists, people like Terasaki for humans or Snell for mice? Makes run of the mill immunology look like a cake walk.